146 related articles for article (PubMed ID: 23334893)
1. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.
Spencer ES; Johnston RB; Gordon RR; Lucas JM; Ussakli CH; Hurtado-Coll A; Srivastava S; Nelson PS; Porter CR
Prostate; 2013 Jun; 73(9):905-12. PubMed ID: 23334893
[TBL] [Abstract][Full Text] [Related]
2. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.
Huang KC; Dolph M; Donnelly B; Bismar TA
Clin Transl Oncol; 2014 Nov; 16(11):973-9. PubMed ID: 24796295
[TBL] [Abstract][Full Text] [Related]
3. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
[TBL] [Abstract][Full Text] [Related]
4. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
Hoogland AM; Jenster G; van Weerden WM; Trapman J; van der Kwast T; Roobol MJ; Schröder FH; Wildhagen MF; van Leenders GJ
Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
[TBL] [Abstract][Full Text] [Related]
5. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
7. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.
Cullen J; Young D; Chen Y; Degon M; Farrell J; Sedarsky J; Baptiste W; Rosen P; Tolstikov V; Kiebish M; Kagan J; Srivastava S; Kuo HC; Moncur JT; Rosner IL; Narain N; Akmaev V; Petrovics G; Dobi A; McLeod DG; Srivastava S; Sesterhenn IA
Eur Urol Focus; 2018 Dec; 4(6):818-824. PubMed ID: 28753864
[TBL] [Abstract][Full Text] [Related]
8. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
[TBL] [Abstract][Full Text] [Related]
9. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
11. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
12. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
Lippolis G; Edsjö A; Stenman UH; Bjartell A
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
[TBL] [Abstract][Full Text] [Related]
13. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.
Schaefer G; Mosquera JM; Ramoner R; Park K; Romanel A; Steiner E; Horninger W; Bektic J; Ladurner-Rennau M; Rubin MA; Demichelis F; Klocker H
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):132-8. PubMed ID: 23381693
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
Gopalan A; Leversha MA; Satagopan JM; Zhou Q; Al-Ahmadie HA; Fine SW; Eastham JA; Scardino PT; Scher HI; Tickoo SK; Reuter VE; Gerald WL
Cancer Res; 2009 Feb; 69(4):1400-6. PubMed ID: 19190343
[TBL] [Abstract][Full Text] [Related]
16. Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.
Szász AM; Majoros A; Rosen P; Srivastava S; Dobi A; Szendrői A; Kulka J; Nyirády P
Int Urol Nephrol; 2013 Jun; 45(3):727-33. PubMed ID: 23686669
[TBL] [Abstract][Full Text] [Related]
17. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
[TBL] [Abstract][Full Text] [Related]
18. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]